ProQR Announces Highlights from Analyst Event
18 nov. 2021 16h01 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR to Webcast Virtual Analyst Event on November 18
11 nov. 2021 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Upcoming Investor Conferences in November and December
08 nov. 2021 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Third Quarter 2021 Operating and Financial Results
04 nov. 2021 07h00 HE
|
ProQR Therapeutics N.V.
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022Five-target collaboration with Lilly highlights significant potential of...
ProQR Appoints Theresa Heggie as Chief Commercial Officer
04 oct. 2021 08h00 HE
|
ProQR Therapeutics N.V.
Senior leader with extensive global rare disease commercialization experienceTop-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 ...
ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
08 sept. 2021 16h15 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of...
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
08 sept. 2021 16h01 HE
|
ProQR Therapeutics N.V.
Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR’s proprietary Axiomer® RNA editing platformProQR to receive $50 million consisting of upfront...
ProQR Announces Virtual Presentation at EURETINA 2021
06 sept. 2021 16h15 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces Upcoming Investor Conferences
03 sept. 2021 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
11 août 2021 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...